In reSURFACE 1 (n=772), at week 12, 62% in the 200 mg group and 64%) in the 100 mg group achieved PASI 75, compared with 6% in the placebo group (p<0.0001 for comparisons of both tildrakizumab groups vs placebo). Additionally, 59% in the 200 mg group and 58% in the 100 mg group achieved PGA responses, compared with 7% in the placebo group (p<0.0001 for comparisons of both tildrakizumab groups vs placebo).
In reSURFACE 2 (n=1090), 66% in the 200 mg group, and 61% in the 100 mg group achieved PASI 75, compared with 6% in the placebo group and 48% in the etanercept group (p<0.0001 for comparisons of both tildrakizumab groups vs placebo; p<0.0001 for 200 mg vs etanercept and p=0.0010 for 100 mg vs etanercept).
In a related editorial, the authors note that these results are similar to those seen with the guselkumab trials, and “Although it is too premature to compare the respective risk–benefit ratios of both drug classes, interleukin-23 and interleukin-17 blocking therapies seem to share commonalities, but also diverge according to some of their immunological effects. In patients with various comorbidities that could affect tolerance, these results show that interleukin 23 blockers, far from being just another number, might well be the right treatment decision, and could represent a significant contribution to stratified approaches. However, long-term extension trials, real-life experience, and studies in psoriatic arthritis will be needed to better define the role of interleukin 23 inhibitors in the treatment algorithm”.